No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
NBIX241220P125000
- 2.41
- +2.26+1506.67%
15min DelayClose Dec 20 16:00 ET
2.41High2.41Low
2.41Open0.15Pre Close1 Volume141 Open Interest125.00Strike Price241.00Turnover0.00%IV9.47%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry2.41Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma56.19Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Neurocrine Is Maintained at Overweight by Barclays
Piper Sandler Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $160
Wedbush Raises Price Target on Neurocrine Biosciences to $154 From $148, Keeps Outperform Rating
Barclays Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $165
Express News | Neurocrine Biosciences Inc : Jefferies Raises Target Price to $168 From $158
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?